Top Pharma News - IgeaHub

Top Pharma News | March – April 2017

Bristol-Myers Squibb Planning Collaboration with GRAIL on Blood-Based Cancer Screening March 1, 2017 Bristol-Myers Squibb Company plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is to detect cancer early when it potentially can be cured. GRAIL aims to develop highly sensitive blood tests that detect cancer in its early … Continue reading Top Pharma News | March – April 2017

Advertisements
AstraZeneca Logo

AstraZeneca Rivals Tesaro Using PARP Inhibitor with Strong Ovarian Cancer Study Results

Mar 14, 2017 The PARP inhibitor of AstraZeneca, Lynparza, delay the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented recently. The strong benefits observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro. … Continue reading AstraZeneca Rivals Tesaro Using PARP Inhibitor with Strong Ovarian Cancer Study Results

Top 10 Pharmaceutical Companies 2017

Top 10 Pharmaceutical Companies 2017

The global pharmaceutical market was estimated in USD 1.1 trillion in 2016. The global market is highly mature and consolidated. The top-10 pharmaceutical companies in this market had share of around 40% in 2016 and approximately 50% considering the top-15. A comparative analysis of the top-15 organizations was used to develop a ranking for these … Continue reading Top 10 Pharmaceutical Companies 2017

AstraZeneca steps up with a $645M deal to partner with Sanofi on a late-stage RSV antibody

March 3, 2017 AstraZeneca has decided to partner with Sanofi on an experimental antibody for RSV. The French pharma giant is paying €120 million upfront and up to €495 million more in development and sales milestones to buy into the program. Now, the two Big Pharmas will split R&D costs for MEDI8897, with AstraZeneca in charge of … Continue reading AstraZeneca steps up with a $645M deal to partner with Sanofi on a late-stage RSV antibody

Top Pharma News - IgeaHub

Top Pharma News | February – March 2017

Amgen Announces the Efficay of Repatha® (Evolocumab) for Reducing the Risk of Cardiovascular Events February 2, 2017 Amgen has announced that the FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial evaluating whether Repatha® (evolocumab) minimizes the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, … Continue reading Top Pharma News | February – March 2017

AstraZeneca Logo

Lynparza meets primary endpoint in Phase III trial in BRCA-mutated metastatic breast cancer

17 February 2017 AstraZeneca has announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations. It was found that patients treated with Lynparza showed a clinically-meaningful and statistically-significant improvement … Continue reading Lynparza meets primary endpoint in Phase III trial in BRCA-mutated metastatic breast cancer

Best Pharmaceutical Companies at a Glance: AstraZeneca

Best Pharmaceutical Companies at a Glance: AstraZeneca

AstraZeneca is a global company involved in the discovery, early- and late-stage development to manufacturing and distribution, and the global commercialization of primary care, specialty care-led and specialty care medicines. The company specializes in   Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA) along with Infection, Neuroscience and Gastrointestinal (ING) disease areas. … Continue reading Best Pharmaceutical Companies at a Glance: AstraZeneca

AstraZeneca expands opportunities for 1st-line lung cancer Immuno-Oncology program

17 January 2017 AstraZeneca has provided an update on its Immuno-Oncology (IO) late-stage clinical development program in 1st-line non-small cell lung cancer (NSCLC), including a refinement of the Phase III MYSTIC trial. The MYSTIC trial was initially designed to assess the benefit of durvalumab monotherapy and durvalumab and tremelimumab (durva + treme) combination therapy versus standard-of-care (SoC) … Continue reading AstraZeneca expands opportunities for 1st-line lung cancer Immuno-Oncology program

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – December 2016

ABOUND Data Explores Safety and Efficacy of ABRAXANE® for the Treatment of Patients with Lung Cancer Dec 6, 2016 Celgene Corporation has announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in patients with advanced non-small cell lung cancer (NSCLC). Interim data presented from the … Continue reading Top Pharma News – December 2016

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma 2016: One Year in Review

Lots of new things happened in the pharmaceutical industry in 2016. At igeahub.com, our mission is to make the pharmaceutical world simple and clear to everyone. We want our readers to have a privileged view on the key player in the healthcare system, and we do our best to keep things simple but highly accurate. The … Continue reading Pharma 2016: One Year in Review